Rio Piedras, Puerto Rico Clinical Trials

A listing of Rio Piedras, Puerto Rico clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 202 clinical trials
featured
A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis

www.MyelofibrosisResearch.com This is a Phase 2 open-label, multicenter study evaluating tolerability and efficacy of navitoclax alone or when added to ruxolitinib in participants with myelofibrosis.

Hospital del Centro Comprensivo de Cancer de la UPR /ID# 222544
 (1.8 away) Contact site
  • 251 views
  • 29 Apr, 2021
  • +134 other locations
featured
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

www.MyelofibrosisResearch.com Myelofibrosis (MF) is a bone marrow illness that affects blood-forming tissues in the body. MF disturbs the body's normal production of blood cells, causing extensive scarring in the bone marrow. This leads to severe anemia, weakness, fatigue, and an enlarged spleen. The purpose of this study is to assess …

Hospital del Centro Comprensivo de Cancer de la UPR /ID# 223281
 (1.8 away) Contact site
  • 164 views
  • 29 Apr, 2021
  • +224 other locations
featured
C2541013 MIRNA NASH  

The study aims to evaluate two, orally administered, investigational agents - PF-06865571 (DGAT2 inhibitor) and the coadministration of PF-06865571 with PF-05221304 (ACC inhibitor). This study is specifically designed to evaluate the effect of a range of doses of DGAT2i alone, and DGAT2i + ACCi, on resolution of NASH or improvement …

FDI Clinical Research
 (1.8 away)
  • 261 views
  • 10 Jun, 2021
  • +58 other locations
featured
Phase 3 Study of MRTX849 vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-12)

This Phase 3 study will evaluate the efficacy of the investigational agent MRTX849 versus docetaxel in patients who have been previously treated for metastatic NSCLC with a KRAS G12C mutation.

refractory non-small cell lung cancer
advanced lung cancer
lung metastases
metastatic non-small cell lung cancer
recurrent non-small cell lung cancer
Mirati Research Site
 (2.0 away) Contact site
  • 0 views
  • 08 Jun, 2021
  • +33 other locations
featured
A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (KRYSTAL-10)

Study 849-010 is an open-label, randomized Phase 3 clinical trial comparing the efficacy of MRTX849 administered in combination with cetuximab versus chemotherapy in the second-line treatment setting in patients with CRC with KRAS G12C mutation.

Fundación de Investigación de Diego (FDI) Clinical Research
 (1.4 away) Contact site
  • 0 views
  • 16 Jun, 2021
  • +17 other locations
featured
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation

Evaluates the safety, tolerability, pharmacokinetics, metabolites, pharmacodynamics, and clinical activity of MRTX849 in patients with advanced solid tumors with a KRAS G12C mutation. MRTX849 is an orally-available small molecule inhibitor of KRAS G12C.

advanced solid tumor
malignant solid tumor
solid tumor
Mirati Research Site
 (4.5 away) Contact site
  • 405 views
  • 08 Mar, 2021
  • +66 other locations
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA)

Rheumatoid Arthritis (RA) is an inflammatory disease of the joints causing pain, stiffness, swelling and loss of joint function. This study evaluates how safe and effective ABBV-154 is in participants treated for moderately to severely active RA. Adverse events and change in the disease activity will be assessed. ABBV-154 is …

antirheumatics
stiffness
rheumatism
methotrexate
GCM Medical Group, PSC /ID# 228981
 (2.3 away) Contact site
  • 0 views
  • 17 Jun, 2021
  • +255 other locations
OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD)

A 2-year phase 3, multicentre, randomised, parallel-group, sham-controlled, double-masked study. Primary efficacy will be determined at Week 52.

COAST Investigational Site
 (6.8 away) Contact site
  • 0 views
  • 13 Jun, 2021
  • +38 other locations
A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis

Study CC-93538-EE-001 is a Phase 3, multicenter, multinational, randomized, double-blind, placebo-controlled induction and maintenance study to evaluate the efficacy and safety of CC- 93538 in adult and adolescent participants with eosinophilic esophagitis (EoE). The study will incorporate a 24-week Induction Phase followed by a 24-week Maintenance Phase. Participants will be …

University of Puerto Rico Fundacion de Investigacion
 (2.9 away) Contact site
  • 0 views
  • 02 May, 2021
  • +200 other locations
Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)

Semaglutide is a medicine studied in patients with NASH. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabetes in many countries. Participants will either get semaglutide or a dummy medicine - which treatment participants get is decided by chance. Participants will need to …

Novo Nordisk Investigational Site
 (1.8 away) Contact site
  • 0 views
  • 16 Jun, 2021
  • +242 other locations